Aerie Pharmaceuticals Completes $275M Convertible Notes Offering

Aerie Pharmaceuticals Completes $275M Convertible Notes Offering

  

Fried Frank acted as counsel to Aerie Pharmaceuticals in its private offering of US$275 million aggregate principal amount of 1.50% convertible senior notes due 2024 and the related capped call transactions. Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases, and other diseases of the eye.
 
The Fried Frank team included corporate partners Andrew B. Barkan, Lee T. Barnum, Darren A. Littlejohn, and Steven G. Scheinfeld; tax partner Joseph E. Fox; corporate special counsel Victoria T. Mazgalev; corporate associates John Lawrence, Hana Nah, and Idan Shkaltz; and tax associate Thomas A. Mitchell.

majormatters-detail.inc